Papers List : AKITO TANAKA, Ph.D, professor.

 

2003-present  Innovation in the Identifications of Drug-targets using Affinity Resins

 M. Mabuchi, M. Haramura, T. Shimizu, T. Nishizaki, A. Tanaka. Selective elution of target protein from affinity resins by a simple reductant with a thiol group. Bioorg Med Chem Lett. 20(24):7361-4 (2010).

 A. Tanaka. Identification of the specific binding proteins of bioactive small compound using affinity resins. Methods Mol Biol. 577:181-95. (2009)

 E. Iwaoka, T. Mori, T. Shimizu, K. Hosoya, A. Tanaka. Improvement of monolithic solid material by utilization of spacer for identification of the target using affinity resins. Bioorg Med Chem Lett. 19(5):1469-72 (2009).

 T. Takahashi, T. Shiyama, K. Hosoya,  A.Tanaka. Development of Chemically Stable Solid-phases for the Target Isolation with Reduced Nonspecific Binding Proteins. Bioorg. Med. Chem. Lett., 16(2), 447-450 (2006).

 K. Yamamoto, A. Yamazaki, M. Takeuchi, A.Tanaka. A versatile method of identifying specific binding proteins on affinity resins. Anal. Biochem., 352(1), 15-23 (2006).

 M. Furuya,  M. Haramura, A.Tanaka. Reduction of Nonspecific Binding Proteins to Self-assembled Monolayer on Gold Surface. Bioorg. Med. Chem., 14(2), 537-543 (2006).

  Mori, K. Hosoya, A.Tanaka.  Isolation of the Whole Target Proteins of FK506 using Affinity Resins from Novel Solid Phases. Anal. Bioanal. Chem. 385(1), 122-127 (2006).

 T. Mori, T. Takahashi, T. Shiyama, A. Tanaka, N. Hira, N. Tanaka, K. Hosoya. An easy preparation of 'monolithic type' hydrophilic solid phase: Capability ofr affnity resin to isolate target proteins.  Bioorg. Med. Chem. 14(16), 5549-5554 (2006).

 東山喜三彦、土屋耕一、原村昌幸、田中明人.         SDS-PAGEゲル内タンパク質を高感度かつ安定的に同定するMSシステム構築の試み. J. Mass Spectrom. Soc. Jpn. 54(3), 109-115 (2006).

 原村昌幸、田中明人.     古くて新しいテーマ：アフィニティ樹脂による網羅的ターゲット探索～非特異的蛋白質の抑制～. ゲノム医学、5 (2), 191-195 (2004).

 T. Shiyama, M. Furuya, A. Yamazaki, T. Terada, A.Tanaka. Design and Synthesis of Novel Hydrophilic Spacers for the Reduction of Nonspecific Binding Proteins on Affinity Resins. Bioorg. Med. Chem., 12(11), 2831-2841 (2004).

 T. Tamura, T. Terada, A.Tanaka. A Quantitative Analysis and Chemical Approach for the Reduction of Nonspecific Binding Proteins on Affinity Resins. Bioconjugate Chem., 14(6), 1222-1230 (2003).

 

2002-present  Identifications of Drug-Targets

 R. Furumai, A. Matsuyama, N. Kobashi, K. H. Lee, M. Nishiyama, H. Nakajima, A. Tanaka, Y. Komatsu, N. Nishino, M. Yoshida, S. Horinouchi. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. 62(17), 4916-4921 (2002).

 

2014-present  Medicinal Chemistry: Development of PCA-1 inhibitor for anti-cancer drug

 M. Mabuchi, T. Shimizu T, M. Ueda, Y. Sasakawa, S. Nakao, Y. Ueda, A. Kawamura, K. Tsujikawa and A. Tanaka. Improving the Bioavailability and Anticancer Effect of the PCA-1/ALKBH3 Inhibitor HUHS015 Using Sodium Salt. In vivo 29: 39-43 (2015)

S. Nakao, M. Mabuchi, T. Shimizu, Y. Itoh, Y. Takeuchi, M. Ueda, H. Mizuno, N. Shigi, I. Ohshio, K Jinguji, Y. Ueda, M. Yamamoto, T. Furukawa, S. Aoki, K. Tsujikawa, A. Tanaka. Design and synthesis of prostate cancer antigen-1 (PCA-1/ALKBH3) inhibitors as anti-prostate cancer drugs. Bioorg Med Chem Lett. 24(4):1071-4 (2014).

 

2003-present  Medicinal Chemistry: Development of DCP-LA (formerly FR236924)

 T. Kanno, A. Tanaka, T. Nishizaki. Linoleic Acid Derivative DCP-LA Ameliorates Stress-Induced Depression-Related Behavior by Promoting Cell Surface 5-HT1A Receptor Translocation, Stimulating Serotonin Release, and Inactivating GSK-3β Mol Neurobiol. 2014 May 1. [Epub ahead of print]

A. Tsuchiya, T. Kanno, T. Shimizu, S. Nakao, A. Tanaka, T. Nishizaki. DCP-LA-phosphatidylinositol and its enantiomer exhibit different bioactivities. Cell Physiol Biochem. 33(2), 300-9 (2014)

T. Kanno, A. Tanaka, T. Shimizu, T. Nakano, T. Nishizaki. 1-[2-(2-Methoxyphenylamino) ethylamino]-3-(naphthalene-1-yloxy)propan-2-ol as a potential anticancer drug. Pharmacology. 91(5-6), 339-45 (2013)

 T. Kanno, A. Tsuchiya, A. Tanaka, T. Nishizaki. The linoleic acid derivative DCP-LA increases membrane surface localization of the α7 ACh receptor in a protein 4.1N-dependent manner. Biochem J. 450(2):303-9 (2013)

 T. Kanno, A. Tanaka, T. Nishizaki. Linoleic acid derivative DCP-LA stimulates vesicular transport of α7 ACh receptors towards surface membrane. Cell Physiol Biochem. 30(1):75-82. (2012)

T. Kanno, T. Yaguchi, T. Shimizu, A. Tanaka, T. Nishizaki. 8-[2-(2-Pentyl-cyclopropylmethyl) -cyclopropyl]-octanoic acid and its diastereomers improve age-related cognitive deterioration. Lipids. 47(7):687-95. (2012)

 T. Shimizu, T. Kanno, A. Tanaka, T. Nishizaki.α, β-DCP-LA selectively activates PKC-ε and stimulates neurotransmitter release with the highest potency among 4 diastereomers. Cell Physiol Biochem. 27(2):149-58. (2011)

 T. Kanno, T. Yaguchi, T. Nagata, A. Tanaka, T. Nishizaki. DCP-LA stimulates AMPA receptor exocytosis through CaMKII activation due to PP-1 inhibition. J Cell Physiol. 221(1), 183-8. (2009)

 T. Yaguchi, T. Nagata, T. Mukasa, H. Fujikawa, H. Yamamoto, S. Yamamoto, H. Iso, A. Tanaka, T. Nishizaki. The linoleic acid derivative DCP-LA improves learning impairment in SAMP8. Neuroreport. 17(1), 105-108 (2006).

 Kanno T, Yamamoto H, Yaguchi T, Hi R, Mukasa T, Fujikawa H, Nagata T, Yamamoto S, Tanaka A, Nishizaki T. The linoleic acid derivative DCP-LA selectively activates PKC-epsilon, possibly binding to the phosphatidylserine binding site. J Lipid Res. 47(6), 1146-56 (2006).

 T. Yaguchi, S. Yamamoto,T.  Nagata, T. Kanno, A. Tanaka, T. Nishizaki. Effects of cis-unsaturated free fatty acids on PKC- activation and nicotinic ACh receptor responses. Mol. Brain Res. 133(2), 320-324 (2005).

 T. Kanno, T. Yaguchi, S. Yamamoto, H. Yamamoto, H. Fujikawa, T. Nagata, A. Tanaka, T. Nishizaki. 8-[2-(2-pentyl-cyclopropylmethyl)-cyclopropyl]octanoic acid stimulates GABA release from interneurons projecting to CA1 pyramidal neurons in the rat hippocampus via pre-synaptic α7 acetylcholine receptors. J. Neurochem 95(3), 695-702 (2005).

 S. Yamamoto, T. Kanno, T. Nagata, T. Yaguchi, A. Tanaka, T. Nishizaki. The linoleic acid derivative FR236924 facilitates hippocampal synaptic transmission by enhancing activity of presynaptic a7 acetylcholine receptors on the glutamatergic terminals. Neuroscience 130(1), 207-213 (2005).

 N. Nagata, S. Yamamoto, T. Yaguchi, H. Iso, A. Tanaka, T. Nishizaki. The newly synthesized linoleic acid derivative DCP-LA ameliorates memory deficits in animal models treated with amyloid- peptide and scopolamine. Psychogeriatrics 5(4), 122-126 (2005).

 Ohta K, Miyamoto H, Yaguchi T, Nagai K, Yamamoto S, Nomura T, Tanaka A, Nishizaki T. Stearic acid facilitates hippocampal neurotransmission by enhancing nicotinic ACh receptor responses via a PKC pathway. Brain Res Mol Brain Res. 119(1), 83-9 (2003).

 Tanaka A, T.Nishizaki  The Newly Synthesized Linoleic Acid Derivative FR236924 Induces a Long-Lasting Facilitation of Hippocampal Neurotransmission by Targeting Nicotinic Acetylcholine Receptors.  Bioorg. Med. Chem Lett. 13(6), 1037-1040 (2003).

 

1992-1993  Visiting Scientist for Stuart L. Schreiber Labs in Harvard University

 F. A. Gomez, J. K. Chen, A. Tanaka, S. L. Schreiber, G. M. Whitesides. Affinity Capillary Electrophoresis: Insights into the Binding of SH3 Domains by Peptides. Derived from an SH3-Binding Protein. J. Org. Chem., 59(10), 2885-2886 (1994).

 Albers MW, Williams RT, Brown EJ, Tanaka A, Hall FL, Schreiber SL. FKBP-Rapamycin Inhibits a Cyclin-dependent Kinase Activity and a Cyclin D1-Cdk. Association in Early G1 of an Osteosarcoma Cell. J. Biol. Chem., 268(30), 22825-22829 (1993).

 Albers MW, Brown EJ, Tanaka A, Williams RT, Hall FL, Schreiber SL.   An FKBP-Rapamycin-Sensitive, Cyclin-Dependent Kinase Activity that Correlates with the FKBP-Rapamycin-Induced G1 Arrest Point in MG-63 Cells.       Ann N Y Acad Sci. 696, 54-62 (1993).

 J. K. Chen, W. S. Lane, A. W. Brauer, A. Tanaka, S. L. Schreiber. Biased Combinatorial Libraries: Novel Ligands for the SH3 Domain of Phosphatidylinositol 3-Kinase.      J. Amer. Chem. Soc., 115(26), 12591-12592 (1993).

 

1994-1996  Development of Novel Descriptor for Hydrophobicity: logPmw (water/micellar)

 Tanaka A, Murata M, Fujiwara H. QSAR Study of the Peptidic Fibrinogen Inhibitors FK633, FR158999 and Related Derivatives, Using a Novel and Useful Hydrophobic Descriptor (logPmw ).Bioorg. Med. Chem Lett. 8(18), 2483-2488 (1998).

 Tanaka A, Fujiwara H. Quantitative Structure-Activity Relationship Study of Fibrinogen Inhibitors, 4-(4-Amidinophenoxy)butanoylaspartylvaline (FK633) Derivatives, Using A Novel Hydrophobic Descriptor. J. Med. Chem., 39(25), 5017-5020 (1996).

 Tanaka A, Nakamura K, Nakanishi I, Fujiwara H.  A Novel and Useful Descriptor for Hydrophobicity,Partition Coefficient Micellar-Water, and Its Application to A QSAR Study of Antiplatelet Agents. J. Med. Chem., 37(26), 4563-4566 (1994).

 

1995-1998  SBDD & Rational Drug Design

 Tanaka A, Rational drug design of the fibrinogen inhibitors FK633 and FR158999. Drugs of the Future 23(3), 291-299 (1998).

 Tanaka A, Hiroyoshi Sakai, Takatoshi Ishikawa, Toshiaki Aoki, Yukio Motoyama, Hisashi Takasugi  Design, Synthesis, and Evaluation of Orally Active Fibrinogen Inhibitors. Bioorg. Med. Chem Lett. 7(5), 521-526 (1997).

 A. Tanaka, H. Sakai, T. Ishikawa, I. Nakanishi, M. Ohkubo, T. Aoki, Y. Motoyama and H. Takasugi. Design, Synthesis, and Evaluation of Fibrinogen Inhibitors, -(p-Amidinophenoxy) alkanoylaspartic acid Derivatives. Bioorg. Med. Chem. Lett., 6(13), 1443-1448 (1996).

 H. Oyasu, I. Nakanishi, A. Tanaka, K. Murano, M. Matsuo. Conformational studies on the four stereoisomers of the novel anticholinergic 4-(dimethylamino)-2-phenyl-2 -(2-pyridyl) pentanamide. J.Comput.-Aided Mol. Des., 9(2), 171-180 (1995).

 

1986-1988  Research on Inter-Molecular Interactions by in silico Methods

 T. Takagi, A. Tanaka, M. Tani, H. Maezaki, H. Fujiwara, Y. Sasaki              Development and Applications for the Simulator of Intermolecular Potentials. II. Hydration Effects on the Conformation of Tyramine. Bull. Chem. Soc. Jpn., 61(2), 329-332 (1988).

 T. Takagi, A. Tanaka, S. Matsuo, H. Maezaki, M. Tani, H. Fujiwara, Y. Sasaki. Computational Studies on CH/π Interactions. J. Chem. Soc. Perkin Trans. II, 1015-1018 (1987).

 T. Takagi, A. Tanaka, S. Maeda, S. Matsuo, H. Fujiwara, Y. Sasaki. A Novel Development for the Simulator of Intermolecular Potentials. Bull. Chem. Soc. Jpn., 59, 1317-1320 (1986).

 

1985-1999  Medicinal Chemistry: Development of Antiplatelet Drug

 T. Aoki, K. Harada, J. Seki, A. Tanaka, H. Takasugi, Y. Motoyama FK633: a potent and selective platelet GPIIb/IIIa antagonist. Cardiovasc. Drug Rev., 17(2), 147-159 (1999).

 Aoki T, Tomiyama Y, Honda S, Senzaki K, Tanaka A, Okubo M, Takahashi F, Takasugi H, Seki J. Difference of (Ca2+)i movements in platelets stimulated by thrombin and TRAP. The involvement of aIIbIII-mediated TXA2 synthesis. Thromb. Haemostasis, 79(6), 1184-1190 (1998).

 Aoki T, Cox D, Senzaki K, Seki J, Tanaka A, Takasugi H, Motoyama Y. Comparison of the antithrombotic effects of FK633, GPIIb/IIIa antagonist, and aspirin in a guinea pig thrombosis model. Thromb. Res. 89(3), 129-136 (1998).

 Aoki T, Cox D, Senzaki K, Seki J, Tanaka A, Takasugi H, Motoyama Y. The Anti-platelet and Anmti-Thrombotic Effects of FK633, A Peptide-Mimetic GPIIb/IIIa Antagonist. Thromb. Res., 81(4), 439-450 (1996).

 Tanaka A, Rational drug design of the fibrinogen inhibitors FK633 and FR158999. Drugs of the Future 23(3), 291-299 (1998).

 Tanaka A, Sakai H, Motoyama Y, Ishikawa T, Takasugi H. Antiplatelet Agents Based on Cyclooxygenase Inhibition without Ulcerogenesis. Evaluation and Synthesis of 4,5-Bis(4-methoxyphenyl)-2-substituted-thiazoles. J. Med. Chem., 37(8), 1189-1199 (1994).

 Tanaka A, Sakai H, Ishikawa T, Motoyama Y, Takasugi H. Studies on Antiplatelet Agents. V. Synthesis and Structure-Activity Relationship of 3-Substituted 5,6-Bis(4-methoxyphenyl)-1,2,4 -triazines. Chem. Pharm. Bull., 42(9), 1835-1840 (1994).

 Tanaka A, Motoyama Y, Takasugi H. Studies on Antiplatelet Agents. IV. A Series of 2-Substituted 4,5-Bis-(4-methoxyphenyl)-pyrimidines as Novel Anti-platelet Agents. Chem. Pharm. Bull., 42(9), 1828-1834 (1994).

 Tanaka A, Ito K, Nishino S, Motoyama Y, Takasugi H. Studies on Antiplatelet Agents. II. Synthesis and Platelet-Inhibitory Activity of 5-Methyl-4-(3-pyridyl)-2-(substituted-Benzimidazol -5-yl)imidazoles. Chem. Pharm. Bull., 42(3), 560-569 (1994).

 Dohi M, Sakata Y, Seki J, Namikawa Y, Fujisaki J, Tanaka A, Takasugi H, Motoyama Y, Yoshida K. The anti-platelet actions of FR122047, a novel cyclooxygenase inhibitor. Eur J Pharmacol. 243(2), 179-184 (1993).

 Tanaka A, Ito K, Nishino S, Motoyama Y, Takasugi H Studies on Antiplatelet Agents. I. Synthesis and Platelet Inhibitory Activity of 5-Alkyl-2-aryl-4-pyridylimidazoles. Chem. Pharm. Bull., 40(12), 3206-3213 (1992).

 

 

1993-1999  Combinatorial Chemistry

 K.Mikami, K. Ding, A. Ishii, A. Tanaka, N. Sawada, K. Kudo. Super High Throughput Screening (SHTS) of Combinatorial Libraries of Chiral Ligands and Activators by HPLC-CD and Combinatorial Chemistry Factory. Chromatography, 20(1), 65-70 (1999).

 J. K. Chen, W. S. Lane, A. W. Brauer, A. Tanaka, S. L. Schreiber. Biased Combinatorial Libraries: Novel Ligands for the SH3 Domain of Phosphatidylinositol 3-Kinase.      J. Amer. Chem. Soc., 115(26), 12591-12592 (1993).

 

Others

 T. Nishizaki, T. Kanno, A. Tsuchiya, Y. Kaku, T. Shimizu, A. Tanaka. 1-[2-(2-Methoxyphenylamino)ethylamino]-3-(naphthalene-1- yloxy)propan-2-ol May Be a Promising Anticancer Drug. Molecules. 19(12):21462-21472. Review. (2014)

 Y. Kaku, H. Nagaya, A. Tsuchiya, T. Kanno, A. Gotoh, A. Tanaka, T. Shimizu, S. Nakao, C. Tabata , T. Nakano, T. Nishizaki. Newly synthesized anticancer drug HUHS1015 is effective on malignant pleural mesothelioma. Cancer Sci. 105(7), 883-9 (2014)

 A. Tsuchiya, T. Kanno, H. Nagaya, T. Shimizu, A. Tanaka, T. Nishizaki. PTP1B inhibition causes Rac1 activation by enhancing receptor tyrosine kinase signaling. Cell Physiol Biochem. 33(4), 1097-105. (2014)

 A. Tsuchiya, T. Kanno, T. Shimizu, S. Nakao, A. Tanaka, C. Tabata, T. Nakano, T. Nishizaki. A novel PP2A enhancer induces caspase-independent apoptosis of MKN28 gastric cancer cells with high MEK activity. Cancer Lett. 347(1), 123-8. ( 2014)

 T. Kanno, A. Tsuchiya, T. Shimizu, A. Tanaka, T. Nishizaki. Indomethacin serves as a potential inhibitor of protein phosphatases. Cell Physiol Biochem. 30(4), 1014-22. ( 2012)

 T. Nishimoto, T. Kanno, T. Shimizu, A. Tanaka, T. Nishizaki. Regulation of GluA1 AMPA receptor through PKC phosphorylation induced by free fatty acid derivative HUHS2002. Lipids. 48(1), 23-8 (2012).

 T. Kanno, A. Tsuchiya, T. Shimizu, A. Tanaka, T. Nishizaki. Novel indomethacin action: selective and direct activation of protein kinase C-ε. Cell Physiol Biochem. 30(3), 771-7. (2012)

 T. Kanno, T. Shimizu, A. Tanaka, T. Nishimoto, T. Nishizaki. Free fatty acid derivative HUHS2002 potentiates α7 ACh receptor responses through indirect activation of CaMKII. Lipids. 47(9), 865-71. (2012)

 T. Kanno, T. Yaguchi, T. Nagata, T. Shimizu, A. Tanaka, T. Nishizaki. Indomethacin enhances learning and memory potential by interacting with CaMKII. J Cell Physiol. 227(3), 919-26. (2012)

 R. Tanaka, M. Haramura, A. Tanaka, N. Hirayama.        Structure of Fipexide Hydrochloride Monohydrate.  Anal. Sci. 22, x31-x32 (2006).

 R. Tanaka, M. Haramura, A. Tanaka, N. Hirayama. Structure of Etophylline. Anal. Sci. 21, x165-x166 (2005).

 R. Tanaka, M. Haramura, A. Tanaka, N. Hirayama. Structure of Pimethixene Maleate. Anal. Sci. 21, x163-x164 (2005).

 R. Tanaka, M. Haramura, A. Tanaka, N. Hirayama. Structure of Flurandrenolide.  Anal. Sci. 21, x161-x162 (2005).

 R. Tanaka, M. Haramura, A. Tanaka, N. Hirayama. Structure of Nadolol.  Anal. Sci. 21, x159-x160 (2005).

 R. Tanaka, M. Haramura, A. Tanaka, N. Hirayama. Structure of Guanethidine Monosulfate. Anal. Sci. 21, x111-x112 (2005).

 R. Tanaka, M. Haramura, A. Tanaka, N. Hirayama. Structure of Trimetazidine. Anal. Sci. 21, x3-x4 (2005).

 R. Tanaka, T. Akimoto, M. Haramura, A. Tanaka, N. Hirayama. Crystal Structure of Hydroflumethiazide. Anal. Sci. 20, x139-x140 (2004).

 R. Tanaka, T. Akimoto, M. Haramura, A. Tanaka, N. Hirayama. Crystal Structure of Dantrolene. Anal. Sci. 20, x97-x98 (2004).

 R. Tanaka, T. Akimoto, M. Haramura, A. Tanaka, N. Hirayama. Crystal Structure of Minoxidil. Anal. Sci. 20, x29-x30 (2004).

 R. Tanaka, M. Haramura, A. Tanaka, T. Akimoto, N. Hirayama. Crystal Structure of 2-(3-Carboxypropyl)-6-(4-hydroxyphenyl)-3H-pyridazin -3-ylidene-ammonium bromide         . Anal. Sci. 20, x41-x42 (2004).

 R. Tanaka, M. Haramura, A. Tanaka N. Hirayama. Structure of Gefitinib. Anal. Sci. 20, x173-x174 (2004).

 R. Tanaka, K. Horio, M. Haramura, A. Tanaka, N. Hirayama. Structure of Nifenazone. Anal. Sci. 20, x171-x172 (2004).

 K. Horio, R. Tanaka, H. Akama, M. Haramura, A. Tanaka, T. Akimoto, N. Hirayama. Crystal Structure of Carisoprodol. Anal. Sci. 20, x43-x44 (2004).

 M. Haramura, A. Tanaka, T. Akimoto, N. Hirayama. Crystal Structure of Streptozocin. Anal. Sci. 19, x77-x78 (2003).

 M. Haramura, A. Tanaka, T. Akimoto, N. Hirayama. Crystal Structure of Clobetasol Propionate. Anal. Sci. 19, x37-x38 (2003).

 M. Haramura, A. Tanaka, T. Akimoto, N. Hirayama. Crystal Structure of Dichlorphenamide. Anal. Sci. 19, x35-x36 (2003).

 M. Haramura, A. Tanaka, T. Akimoto, N. Hirayama. Crystal Structure of Vigabatrin. Anal.Sci.19, x9-x10 (2003).